March

Panama City Physician Pays $225,000 to Settle Allegations that He Overprescribed Controlled Substances (March 21, 2023)

Scottsdale Research Institute (PDF) (March 23, 2023)

Lonza Tampa, LLC (PDF) (March 23, 2023)

Caligor Coghlan Pharma Services (PDF) (March 23, 2023)

Patheon Pharmaceuticals Inc. (PDF) (March 23, 2023)

Meridian Medical Technologies, LLC (PDF) (March 23, 2023)

Lipomed (PDF) (March 23, 2023)

Purisys, LLC (PDF) (March 23, 2023)

Myonex Inc. (PDF) (March 23, 2023)

Scottsdale Research Institute (PDF) (March 23, 2023)

Sigma Aldrich Research Biochemicals, Inc. (PDF) (March 23, 2023)

Shahid Masood, M.D.; Decision and Order (PDF) (March 22, 2023)

Heather M. Entrekin, DVM; Decision and Order (PDF) (March 22, 2023)

Christina Collins, APRN; Decision and Order (PDF) (March 22, 2023)

Karl Kauffman, M.D.; Decision and Order (PDF) (March 22, 2023)

Final Order: Placement of Brorphine in Schedule I (PDF) (March 6, 2023)

60-Day Notice: Application for Registration and Application for Registration Renewal; DEA Forms 224, 224A (PDF) (March 3, 2023)

Proposed Rule: Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation (PDF) (March 1, 2023)

Proposed Rule: Expansion of Induction of Buprenorphine via Telemedicine Encounter (PDF) (March 1, 2023)

February

Stepan Company (PDF) (February 24, 2023)

S&B Pharma LLC (PDF) (February 24, 2023)

Siemens Healthcare Diagnostics, Inc. (PDF) (February 24, 2023)

Sterling Wisconsin, LLC (PDF) (February 24, 2023)

S&B Pharma LLC (PDF) (February 24, 2023)

Scottsdale Research Institute (PDF) (February 24, 2023)

Sigma Aldrich Company LLC (PDF) (February 17, 2023)

Veranova, L.P. (PDF) (February 17, 2023)

Avant Biopharmaceuticals (PDF) (February 17, 2023)

Mylan Inc. (PDF) (February 17, 2023)

Persist Al Formulations Corp (PDF) (February 17, 2023)

Proposed Rule: Controlled Substances Ordering System (CSOS) Modernization (PDF) (February 2, 2023)

Reynaldo De Los Angeles, M.D.; Decision and Order (PDF) (February 2, 2023)

Dylan E. O'Connor, M.D.; Decision and Order (PDF) (February 2, 2023)

Fernando Mendez, P.A.; Decision and Order (PDF) (February 2, 2023)

Ester Mark, M.D.; Decision and Order (PDF) (February 2, 2023)

January 2023

Globyz Pharma, LLC (PDF) (January 30, 2023)

Janssen Pharmaceuticals Inc. (PDF) (January 23, 2023)

Mylan Pharmaceuticals, Inc. (PDF) (January 23, 2023)

Siegfried USA, LLC (PDF) (January 23, 2023)

Maridose LLC (PDF) (January 23, 2023)

Janssen Pharmaceuticals Inc. (PDF) (January 23, 2023)

Medi-Physics Inc. dba GE Healthcare (PDF) (January 23, 2023)

Sunny Enterprises Inc. (PDF) (January 23, 2023)

Organic Consultants LLC DBA Cascade Chemistry (PDF) (January 23, 2023)

Kinetochem LLC (PDF) (January 20, 2023)

Siegfried USA, LLC (PDF) (January 20, 2023)

VA Cooperative Studies Program (PDF) (January 20, 2023)

Noramco (PDF) (January 20, 2023)

Navinta LLC (PDF) (January 20, 2023)

Soo Labs II, Inc. (PDF) (January 20, 2023)

Sualeh Ashraf, M.D.; Decision and Order (PDF) (January 6, 2023)

Valerie L. Augustus, M.D.; Decision and Order (PDF) (January 6, 2023)

Sohail Mamdani, M.D.; Decision and Order (PDF) (January 6, 2023)

60-Day Notice: Diversion Control Division Information Technology Modernization Effort (PDF) (January 4, 2023)

December

Isosciences, LLC (PDF) (December 28, 2022)

Proposed Amendment: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I (PDF) (December 23, 2022)

Final Rule: Removal of Fenfluramine From Control (PDF) (December 23, 2022)

Stepan Company; Correction (PDF) (December 15, 2022)

Sterling Pharma USA, LLC (PDF) (December 12, 2022)

Scottsdale Research Institute (PDF) (December 12, 2022)

VHG Labs dba LGC Standards (PDF) (December 12, 2022)

Lyndra Therapeutics (PDF) (December 12, 2022)

Final Rule: Placement of Methiopropamine in Schedule I (PDF) (December 9, 2022)

Final Order: Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2023 (PDF) (December 2, 2022)

Alm Management (PDF) (December 2, 2022)

Attitude Wellness (PDF) (December 2, 2022)

Kerry Farms LLC (PDF) (December 1, 2022)

November

Final Rule; Correction: Default Provisions for Hearing Proceedings Relating to the Revocation, Suspension, or Denial of a Registration (PDF) (November 29, 2022)

Final Rule: Placement of Mesocarb in Schedule I (PDF) (November 22, 2022)

Final Rule: Removal of [¹⁸F]FP-CIT From Control (PDF) (November 21, 2022)

Final Rule: Placement of Zipeprol in Schedule I (PDF) (November 21, 2022)

Adley Dasilva, P.A.; Decision and Order (PDF) (November 18, 2022)

Berkshire Roots, Inc. (PDF) (November 18, 2022)

Vici Health Sciences, LLC (PDF) (November 18, 2022)

Final Rule: Placement of Amineptine in Schedule I (PDF) (November 17, 2022)

Final Rule: Default Provisions for Hearing Proceedings Relating to the Revocation, Suspension, or Denial of a Registration (PDF) (November 14, 2022)

Final Rule: Specific Listing for 1-boc-4-AP, a Currently Controlled List I Chemical (PDF) (November 9, 2022)

Final Rule: Placement of Ganaxolone in Schedule V (PDF) (November 9, 2022)

Nicky Shah, M.D.; Decision and Order (PDF) (November 8, 2022)

George M. Douglass, M.D.; Decision and Order (PDF) (November 8, 2022)

Gerald M. Baltz, N.P.; Decision and Order (PDF) (November 8, 2022)

Chattem Chemicals, Inc.; Correction (PDF) (November 8, 2022)

Final Rule: Technical Correction to Regulation Regarding Registration Exception for Officials (PDF) (November 7, 2022)

Organix Chemistry Solutions LLC (PDF) (November 4, 2022)

October

Nanosyn Inc. (PDF) (October 31, 2022)

Noramco (PDF) (October 31, 2022)

Curia New York, Inc. (PDF) (October 31, 2022)

Mylan Technologies, Inc. (PDF) (October 31, 2022)

Fisher Clinical Services, Inc. (PDF) (October 24, 2022)

Morrison Newfound Valley Manufacturing (PDF) (October 24, 2022)

Rocky Mountain Biotech, LLC (PDF) (October 24, 2022)

Nexus Pharmaceuticals, Inc. (PDF) (October 24, 2022)

Benuvia Manufacturing, Inc. (PDF) (October 24, 2022)

Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2023 (PDF) (October 18, 2022)

National Center for Natural Products Research (PDF) (October 18, 2022)

Organic Standards Solutions International, LLC (PDF) (October 18, 2022)

Irvine Labs, Inc. (PDF) (October 13, 2022)

Groff NA Hemplex LLC (PDF) (October 13, 2022)

National Center for Natural Products Research (PDF) (October 13, 2022)

Fisher Clinical Services, Inc. (PDF) (October 13, 2022)

Eli-ElSohly Laboratories (PDF) (October 11, 2022)

Hybrid Pharma (PDF) (October 11, 2022)

Groff NA Hemplex LLC (PDF) (October 11, 2022)

Cambrex High Point, Inc. (PDF) (October 11, 2022)

Curia Missouri, Inc. (PDF) (October 11, 2022)

Curia Wisconsin, Inc. (PDF) (October 11, 2022)

Curia New York, Inc. (PDF) (October 11, 2022)

Chattem Chemicals, Inc. (PDF) (October 11, 2022)

VICI Health Sciences, LLC (PDF) (October 11, 2022)

Cambridge Isotope Laboratories Inc. (PDF) (October 7, 2022)

Cardinal Health, DBA Specialty Pharmaceutical Service (PDF) (October 7, 2022)

Fresenius Kabi USA, LLC (PDF) (October 7, 2022)

Cambrex High Point, Inc. (PDF) (October 7, 2022)